已收盤 11-20 16:00:00 美东时间
-0.410
-5.61%
Iovance Biotherapeutics granted stock options for 175,840 shares to 22 new, non-executive employees on November 19, 2026, under its 2021 Inducement Plan. The options have an exercise price of $7.31, vesting over three years with one-third vesting on the first anniversary of employment and the remainder in eight quarterly installments. Iovance is a leader in developing TIL therapies, with Amtagvi® approved for advanced melanoma and available at ov...
11-20 22:15
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give...
11-20 19:12
今日重点评级关注:瑞银:维持Liberty Media"中性"评级,目标价从110美元升至1116美元;杰富瑞:维持伊诺维奥制药"买入"评级,目标价从3美元升至8美元
11-09 14:00
The latest update is out from Iovance Biotherapeutics ( ($IOVA) ). On November ...
11-06 07:26
华盛资讯11月6日讯,Iovance Biotherapeutics公布2026财年Q3业绩,公司Q3营收1.22亿美元,同比增长80.0%。
11-06 06:20
华盛资讯11月5日讯,Iovance Biotherapeutics公布2026财年Q3业绩,公司Q3营收1.21亿美元,同比增长80.1%,归母净利润亏损0.22亿美元,同比亏损缩窄75.6%。
11-05 22:34
华盛资讯11月5日讯,Iovance Biotherapeutics公布2026财年Q3业绩,公司Q3营收1.21亿美元,同比增长80.1%,归母净利润亏损0.22亿美元,同比亏损缩窄75.6%。
11-05 20:17
Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.09) by 37.5 percent. This is a 80 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $121.460 m...
11-05 20:09
今日重点评级关注:Rosenblatt:维持SiTime"买入"评级,目标价从750美元升至900美元;花旗:维持Madrigal Pharmaceuticals"买入"评级,目标价从725美元升至760美元
11-04 18:17
UBS analyst David Dai maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $7 to $8.
11-04 00:01